These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25165039)

  • 1. Modeling of bounded outcome scores with data on the boundaries: application to disability assessment for dementia scores in Alzheimer's disease.
    Xu XS; Samtani M; Yuan M; Nandy P
    AAPS J; 2014 Nov; 16(6):1271-81. PubMed ID: 25165039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries.
    Xu XS; Samtani MN; Dunne A; Nandy P; Vermeulen A; De Ridder F;
    J Pharmacokinet Pharmacodyn; 2013 Aug; 40(4):537-44. PubMed ID: 23645382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.
    Xu SX; Samtani MN; Russu A; Adedokun OJ; Lu M; Ito K; Corrigan B; Raje S; Brashear HR; Styren S; Hu C
    Alzheimers Dement (N Y); 2015 Sep; 1(2):141-149. PubMed ID: 29854934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional disability in Alzheimer disease: a validation study of the Turkish version of the disability assessment for dementia scale.
    Tozlu M; Cankurtaran M; Yavuz BB; Cankurtaran ES; Kutluer I; Erkek BM; Halil M; Ulger Z; Cosgun E; Ariogul S
    J Geriatr Psychiatry Neurol; 2014 Dec; 27(4):237-46. PubMed ID: 24763071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional disability in Alzheimer disease: a validation study of the Brazilian version of the Disability Assessment for Dementia (DAD-Br).
    Bahia VS; Carthery-Goulart MT; Novelli MM; Kato-Narita EM; Areza-Fegyveres R; Caramelli P; Nitrini R
    Alzheimer Dis Assoc Disord; 2010; 24(3):291-5. PubMed ID: 20473140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort.
    Hsiung GY; Alipour S; Jacova C; Grand J; Gauthier S; Black SE; Bouchard RW; Kertesz A; Loy-English I; Hogan DB; Rockwood K; Feldman HH
    Dement Geriatr Cogn Disord; 2008; 25(6):483-90. PubMed ID: 18417973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
    Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
    J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease.
    van de Beek M; van Steenoven I; Ramakers IHGB; Aalten P; Koek HL; Olde Rikkert MGM; Manniën J; Papma JM; de Jong FJ; Lemstra AW; van der Flier WM
    J Alzheimers Dis; 2019; 70(2):389-397. PubMed ID: 31177218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.
    Gélinas I; Gauthier L; McIntyre M; Gauthier S
    Am J Occup Ther; 1999; 53(5):471-81. PubMed ID: 10500855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Awareness of deficits and anosognosia in Alzheimer's disease].
    Antoine C; Antoine P; Guermonprez P; Frigard B
    Encephale; 2004; 30(6):570-7. PubMed ID: 15738860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Alzheimer's disease progression based on clinical dementia rating scale with missing responses and covariates.
    Das K; Rana S; Roy S;
    J Biopharm Stat; 2018; 28(5):893-908. PubMed ID: 29173033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of potential measures in models of progression in Alzheimer disease.
    McLaughlin T; Buxton M; Mittendorf T; Redekop W; Mucha L; Darba J; Jonsson L; Lacey L; Leibman C
    Neurology; 2010 Oct; 75(14):1256-62. PubMed ID: 20921511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional disability in early Alzheimer's disease - a validation study of the Italian version of the disability assessment for dementia scale.
    De Vreese LP; Caffarra P; Savarè R; Cerutti R; Franceschi M; Grossi E;
    Dement Geriatr Cogn Disord; 2008; 25(2):186-94. PubMed ID: 18196940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and indirect assessments of activities of daily living in behavioral variant frontotemporal dementia and Alzheimer disease.
    Lima-Silva TB; Bahia VS; Carvalho VA; Guimarães HC; Caramelli P; Balthazar ML; Damasceno B; Bottino CM; Brucki SM; Nitrini R; Yassuda MS
    J Geriatr Psychiatry Neurol; 2015 Mar; 28(1):19-26. PubMed ID: 25015849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
    Dyer AH; Murphy C; Segurado R; Lawlor B; Kennelly SP;
    J Gerontol A Biol Sci Med Sci; 2020 Apr; 75(5):987-994. PubMed ID: 31613323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study.
    Hager K; Baseman AS; Nye JS; Brashear HR; Han J; Sano M; Davis B; Richards HM
    Alzheimers Res Ther; 2016 Nov; 8(1):47. PubMed ID: 27846868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
    Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
    J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.